Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Receivables - Other: 2022-2025

Historic Receivables - Other for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $2.6 million.

  • Taysha Gene Therapies' Receivables - Other changed negligibly% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.6 million for FY2024, which is negligibly% changed negligibly from last year.
  • Taysha Gene Therapies' Receivables - Other amounted to $2.6 million in Q3 2025, which was down 0.00% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Receivables - Other ranged from a high of $2.6 million in Q1 2022 and a low of $2.6 million during Q1 2022.
  • Over the past 3 years, Taysha Gene Therapies' median Receivables - Other value was $2.6 million (recorded in 2025), while the average stood at $2.6 million.